vasomotor symptoms, postmenopausal
Women's health · 2025–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| estradiol with progesterone Treatment of moderate to severe vasomotor symptoms in postmenopausal women with an intact uterus. | Nov 2025 | Recommended | 33 individuals Advanced Pharmacy Australia · Australasian Menopause Society |
Who spoke
Advanced Pharmacy Australia · Australasian Menopause Society
What the PBS pays
$32M in government benefit over 2024–25, across 1,180,562 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| estradiol with progesterone | $31.6M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.